Cell viability was determined by Trypan blue exclusion on a minimum of 200 cells using a Countess automated cell counter (Invitrogen).
The VLS was designed as a "pragmatic" trial in which the intervention to be tested is overlaid on the background of usual clinical practice, with a minimum of study-related practice constraints, liberal inclusion, and few exclusion criteria.
We focused on the exclusion of pulmonary embolism with a minimum of missed of cases (false negative proportion or failure rate).
The ITT population consisted of all patients giving informed consent, fulfilling the inclusion and exclusion criteria and receiving planned treatment for a minimum of 4 weeks after initiation.
They offered a minimum of 3%% of their monthly salary for type of benefit package with exclusion of some chronic diseases and dental care while the civil servants offered 0.5%% for a comparable type of benefit packages.
Following these exclusions, all participants included in analyses gave a minimum of 12 attended, artefact free epochs per condition.
We estimate that a minimum of ∼1% of previously untested genes (5 of 500 genes surveyed) undergo allelic exclusion in addition to those already known.
We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of seven days.
Assuming exclusion of 20% of patients from the PP population, this required a minimum of 584 randomised patients.
This difference persisted after exclusion of people with a dementia diagnosis and limiting analysis to residents with a minimum of 15 months' registration.
